Home Tags Mersana

Tag: Mersana

What are the next generation ADCs?

In the last decade, there have unprecedented advances in discovery of new cytotoxic warheads of different mechanisms, new linkers with highly stable DARs, warhead...

FDA Clears Mersana’s IND Application for XMT-1536

Focusing on discovering and developing a pipeline of novel antibody-drug conjugates or ADCs based on its proprietary Dolaflexin® platform, Mersana Therapeutics' Investigational New Drug...

XMT-1522 Trial in Progress Data Presented at ASCO

Data from a trials in progress abstract presented during the 2017 annual meeting of the American Society of Clinical Oncology (ASCO) confirmed the continued...

Preclinical Data on XMT-1522 Supports Efficacy and Tolerability

During the 108th Annual Meeting of the American Association for Cancer Research (AACR), held April 1 to 5, 2017, in Washington, D.C, Mersana Therapeutics,...

Best ADC Platform Technology Awarded to Mersana Therapeutics

This week, during the 7th World ADC Conference in San Diengo, Mersana Therapeutics, a biotechnology company focused on discovering and developing a pipeline of...

Mersana and Takeda Expand Partnership to Advance Development of Fleximer® based...

Mersana Therapeutics and Takeda Pharmaceutical Company Limited announced that they have entered a new, expanded, strategic partnership.  Under the terms of the agreement,  Takeda...

XMT-1522 Continues to Demonstrate Complete Tumor Regressions in Multiple HER2-Expressing Breast...

Positive preclinical data for Mersana Therapeutics'  lead product candidate, XMT-1522, demonstrates significant anti-cancer activity in both HER2-positive and HER2 low-expressing tumor models refractory to...

Mersana and Recepta Sign Agreement for Novel Antibody

Cambridge based Mersana Therapeutics and Recepta Biopharma, a clinical stage Brazilian biotechnology company, have entered into an exclusive license agreement in which Mersana will...

Millennium/Takeda Exercises Commercial License Right for Fleximer Technology

Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited has exercised an option to license commercial rights for its first novel Fleximer® antibody-drug conjugate or ADC developed as part of their collaboration with Mersana Therapeutics, announced earlier this year.